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Abstract
Background: Approximately 8–15% epithelial ovarian cancer patients are BRCA1 or BRCA2 germline mutation carriers.
Brazilian inhabitants may have peculiar genetic characteristics associated with ethnic diversity, and studies focusing on
the entire BRCA1/BRCA2 gene sequencing in Brazilian ovarian cancer patients are still lacking. The aim of this study was
to evaluate BRCA1/2 mutations, through entire gene sequencing, in a Brazilian population of women with epithelial
ovarian cancer.
Methods: In a cross sectional study performed in one reference centre for cancer treatment in São Paulo, Brazil, 100
patients diagnosed with epithelial ovarian cancer unselected for family history of breast and/or ovarian cancer were
included. The complete coding sequence of BRCA1/2 genes was evaluated through Next-Generation or capillary
sequencing. Large deletions were investigated through Multiplex Ligation-dependent Probe Amplification (MLPA).
Results: Nineteen pathogenic mutations (BRCA1: n = 17 and BRCA2: n = 2) featuring 14 different mutations, including
two large deletions in BRCA1 (exon 1–2 deleted and exon 5–7 deleted) were identified. Three mutations were detected
more than once (c.3331_3334delCAAG, c.5266dupC and c.4484G > T). Two novel frameshift mutations were identified,
one in BRCA1 (c.961_962delTG) and one in BRCA2 (c.1963_1963delC). BRCA1/2 mutations were seen in 35.5% of the patients
with first and/or second-degree relatives with breast and/or ovarian cancer. Nineteen variants of uncertain significance
(VUS) were detected (BRCA1: n= 2 and BRCA2: n= 17), including five distinct missense variants (BRCA1: c.5348 T > C; BRCA2:
c.2350A >G, c.3515C > T, c.7534C > T, and c.8351G > A).
Conclusions: Among epithelial ovarian cancer patients unselected for family history of cancer, 19% were BRCA1/2 germline
mutation carriers. Almost ¾ of the BRCA mutations, including two large deletions, were detected only once. Our work
emphasizes the need of entire gene sequencing and MLPA screening in Brazil.
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Background
Among the gynaecological malignancies, ovarian cancer
has the highest mortality rate in developed countries
and is the second leading cause of mortality in developing
countries. In Brazil, 6150 new cases of ovarian cancer are
expected in 2016, and in 2013, ovarian cancer accounted
for 3283 deaths, indicating its importance in public health
[1]. One feature that might contribute to this high mortal-
ity rate is that more than 60% of the patients are diag-
nosed in an advanced stage of the disease. [2].
One of the risk factors for ovarian cancer is germline
mutations in BRCA1 or BRCA2 genes, accounting for
approximately 8–15% of ovarian cancer cases worldwide
[3–5]. Although the estimated cumulative incidence of
ovarian cancer by the age of 70 is 40% (95% CI 35–46%)
for BRCA1 and 18% (95% CI 13–23%) for BRCA2 muta-
tion carriers [6], the precise risk estimates vary
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according to the population under study, ascertainment
method and applied statistical technique [7].
Detection of BRCA mutation carriers may benefit both
women who were already diagnosed with ovarian cancer,
as well as their unaffected family members. These pa-
tients may benefit from platinum based chemotherapy
[8] and PARP inhibitors [9], while unaffected family
members may benefit from genetic counselling on risk
reducing surgery, such as salpingo-oophorectomy,
which may reduce their chances of developing ovarian
cancer by 90% [10].
Although some studies evaluated BRCA1/2 mutations
in breast and/or ovarian cancer patients in our country,
only a few of them have performed the entire gene
sequencing, none specifically in ovarian cancer patients
[11–13]. Besides that, for most women with ovarian can-
cer, neither gene sequencing nor genetic counselling is
currently available. Hence, the purpose of our work was
to screen the entire BRCA1 and BRCA2 genes in a series
of patients with epithelial ovarian cancer unselected for
age or family history for breast and/or ovarian cancer
treated in Brazil.
Methods
Patients
Patients were accrued at Instituto do Câncer do Estado
de São Paulo (ICESP) in São Paulo city, Brazil. São Paulo
is the largest city in Brazil and its metropolitan area has
around 18 million people [14]. ICESP integrates the
Brazilian public health network (SUS, Sistema Único de
Saúde), which is responsible for the health care of ¾ of
our population, and is the largest reference centre for
cancer treatment in Latin America [15].
This study was approved by the Institutional Ethics
Committee (Comitê de Ética da Faculdade de Medicina
da Universidade de São Paulo, reference number 132/12
and 172/13) and an informed consent was signed by
each participant.
Patients with invasive epithelial ovarian cancer, who
were undergoing treatment or follow-up in the period
between October 2012 and February 2015 at ICESP,
were invited to participate. Inclusion criteria were inva-
sive epithelial ovarian cancer diagnosis in the period
beginning in January 2009 until the end of the study.
Data regarding the tumour characteristics was obtained
from the patient files.
To characterize our patients, women were asked to
report their family history of breast and ovarian cancer,
birth place and ancestry (defined as place of origin of
direct ancestors, until third degree). Ancestry was con-
sidered unknown if there was no information at all or if
parents were born in Brazil and there was no further
information for at least second-degree ancestors.
Concerning family history of breast and ovarian can-
cer, patients were asked to report information about first
and second-degree relatives. When women were able to
report on two or more female relatives (≥45 years) from
both sides of the family, they were classified as having a
complete informative family history.
DNA extraction from mononuclear cells
Total DNA was extracted from 10 mL blood samples
using Illustra Blood GenomicPrep Mini spin kit (GE/28-
9042-64, GE Healthcare Life Science) following the
instructions of the manufacturer.
BRCA1 and BRCA2 entire gene sequencing
The coding regions and exon-intron boundaries of
BRCA1 and BRCA2 genes were sequenced by Sanger
sequencing (n = 39) or by Next-Generation Sequencing
(NGS) (n = 63). As a matter of comparison, two samples
were analysed by both techniques, and results from both
of them revealed the same single nucleotide substitu-
tions and microdeletions.
Polymerase chain reaction (PCR) amplification and Sanger
sequencing
The complete coding regions of BRCA1 (U14680 or
NM_7294.3) and BRCA2 (U43746 or NM_000059.3),
including 50–100 base pairs (bp) of non-coding
sequences, flanking the 5’ and 3’ ends of each exon, were
amplified by PCR using 33 pairs of primers for BRCA1
gene and 48 pairs of primers for BRCA2 gene previously
employed by other authors (Additional file 1). All patho-
genic mutations were confirmed through a second
Sanger sequencing.
Next-generation sequencing
For the NGS analysis, the Ion AmpliSeq™ BRCA1 and
BRCA2 Panel (Life technologies) was used. The panel
consists of three primer pools (167 amplicons) that tar-
get the entire coding regions, including 10–20 bp of
non-coding sequences, flanking the 5’ and 3’ ends of
each exon. Samples were sequenced on a 314 v2 Ion
Chip taking 12 samples per chip using a Personal Gen-
ome Machine (PGM) sequencer (Ion Torrent™), and the
Ion PGM Sequencing 200 Kit version 2 (Life Technolo-
gies). Data analysis consisting of annotation of single-
nucleotide variants, insertions, deletions, and splice site
alterations was performed using the Ion Reporter™
Server System (Life Technologies). Sequence data were
also visually evaluated through Integrative Genomics
Viewer (IGV). If a nucleotide had coverage under 50x,
the affected region was re-sequenced by Sanger method-
ology. In addition, all pathogenic variants were re-se-
quenced by Sanger methodology for confirmation. Full
details of methods are given in the Additional file 1.
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Multiplex ligation-dependent probe amplification
All patients had their DNA investigated for large rearrange-
ments of BRCA1 and BRCA2 genes, specifically deletions
and duplications, and CHEK2 (c.1100delC) point mutation,
through the Multiplex Ligation-dependent Probe Amplifi-
cation (MLPA) methodology (BRCA1: SALSA® MLPA®
P002 probemix; BRCA2: SALSA® MLPA® P045 BRCA2/
CHEK2 probemix; MRC-Holland, Amsterdam, The
Netherlands), as described on Additional file 1.
Patients showing positive results had DNA samples
analysed by a different set of MLPA probemix
(BRCA1: SALSA® MLPA® P087; BRCA2: SALSA®
MLPA® P077, MRC-Holland, Amsterdam, The
Netherlands).
Classifications of variants
All sequence variants were named according to the no-
menclature proposed by the Human Genome Variation
Society, HGVS [16]. BRCA1 and BRCA2 variants were
searched in five publicly accessible databases. Additionally,
gene variants were submitted to in silico prediction
models, PolyPhen-2 [17], SIFT [18], Align-GVGD [19], for
missense variants; Provean [20] for in-frame deletions,
and Human Splicing Finder [21] to check for intronic and
exonic variants leading to potential splicing defects. Minor
allele frequency was checked in the 1000 Genomes Project
database [22], the Exome Aggregation Consortium
(ExAC) [23], the Global MAF dbSNP [24], the Exome
Variant Server, NHLBI GO Exome Sequencing Project
(ESP) [25]. Minor allele frequency in probands was also
evaluated (Additional file 1: Table S2-S3).
The variants were then classified according to recom-
mendations of the American College of Medical Genet-
ics and Genomics in: pathogenic, likely pathogenic,
benign, likely benign and variant of uncertain signifi-
cance (VUS) [26]. Variants for BRCA1 were also checked
for co-occurrence with known pathogenic mutations in
the same patient. When the VUS were present in two or
more databases and classified as benign (BIC and
ClinVar), not affect function (LOVD), 1-not pathogenic
(LOVD-IARC), 1-neutral (UMD/BRCA Share™) they
were considered as benign on the present analysis.
Results
One hundred women were included, with a median age
at the time of diagnosis of 55.0 years (33–81 years) and
at time of inclusion in this study of 56.5 years (34–81
years). The median interval between date of diagnosis
and date of inclusion in the study was 18 months (1–54
months). Most patients were diagnosed with serous
adenocarcinoma (84%) and advanced stage disease (clin-
ical stages III/IV; 78%), six patients had a prior diagnosis
of breast cancer (Additional file 1: Table S1). Most
women were born in the Southeast region of Brazil
(57%), mainly in Sao Paulo state (48%), including those
born in Sao Paulo city (25%); 28% of the patients were
born in the Northeast region of the country, mainly in
Bahia state (12%) (Table 1). Concerning ancestry, 38% of
Table 1 Clinical and Pathological features of ovarian cancer patients
according to deleterious BRCA1/2 mutations
BRCA 1/2 mut BRCA1/2 wt
n = 19 n = 81
Age at diagnosis, median
(range), years
54 (39–63) 55 (33–81)
Time between diagnosis
and inclusion (months)
23.33 ± 14.53 19.83 ± 13.52
Histology, n (%)
Serous 18 (94.7) 66 (81.5)
Non-serous 1 (5.3) 15 (18.5)
Clinical Stage, n (%)
I/II 0 (0) 21 (25.9)
III/IV 19 (100) 59 (72.8)
Missing 0 (0) 1 (1.2)
Region of origin, n (%)
Southeast 9 (47.4) 48 (59.3)
Northeast 7 (36.8) 21 (25.9)
South 2 (10.5) 8 (9.9)
North 1 (5.3) 1 (1.2)
Abroad 0 (0) 2 (2.4)
Missing 0 (0) 1 (1.2)
Ancestry until 3rd degree, n (%)
Brazilian only 7 (36.8) 31 (38.3)
European only 2 (10.5) 12 (14.8)
Japanese only 1 (5.3) 4 (4.9)
Asian only 0 (0) 1 (1.2)
Brazilian and European 5 (26.3) 16 (19.8)
Brazilian and Indigenous 2 (10.5) 1 (1.2)
Indigenous and European 0 (0) 1 (1.2)
Indigenous and Brazilian
and European
2 (10.5) 1 (1.2)
Brazilian and African 0 (0) 2 (2.5)
Brazilian and African and
European
0 (0) 1 (1.2)
Brazilian and Japanese 0 (0) 2 (2.5)
Unknown 0 (0) 8 (9.9)
Missing 0 (0) 1 (1.2)
Family history for breast and/or
ovarian cancer
Positive (first and/or second-
degree relatives)
11 (57.9) 20 (24.7)
Negative 5 (26.3) 32 (39.5)
Not Completely Known/Unknown 3(15.8) 29 (35.8)
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the patients reported Brazilian only ancestors, 14% and 5%
reported European only or Japanese only ancestors in both
sides of the family, respectively. In addition, 7% of the pa-
tients reported at least one indigenous ancestor, in con-
comitance with Brazilian and/or European ancestries
(Table 1). Thirty-two out of 100 patients were not able to
provide a complete informative family history; 31 of the
remaining 68 patients reported at least one first and/or
second-degree relative with breast and/or ovarian cancer.
Pathogenic mutations in BRCA1 and BRCA2 genes
were detected in 19 patients, 17 in BRCA1 and two in
BRCA2 (Table 2; Additional file 1: Table S2-S3). Muta-
tions in BRCA1, comprised five different frameshift mu-
tations, two of which were present in three different
patients (c.3331_3334delCAAG and c.5266dupC) and
one detected for the first time in the current study
(c.961_962delTG). BRCA1 mutations also included two
nonsense mutations in exon 11; one missense mutation
(c.4484G > T, detected in two patients) and two splice
site variants (c.4675 + 1G > A, in exon 15, and c.5074 +
2 T > C, in exon 17).
BRCA1 rearrangements were identified in two patients
(Table 2). One patient presented one large deletion
involving exons 5, 6 and 7, detected by two different sets
of MLPA probemix (SALSA® MLPA® P002 and SALSA®
MLPA® P087). Another patient displayed an inconclusive
result using SALSA® MLPA® P002 BRCA1 probemix,
which provided questionable low signals for the 1a, 1b
and 2 exons repeatedly, probably due to incomplete
denaturation of the CpG islands near these exons. A
confirmatory MLPA reaction with a second set of probes
(SALSA® MLPA® P087 BRCA1 probemix) corroborated
the presence of this rearrangement.
Pathogenic mutations in BRCA2, both frameshift, were
detected in only two patients, one of them identified for
the first time in the present study (c.1963_1963delC,
exon 11). A suspected deletion of BRCA2 exon 15 was
at first detected, but was not confirmed. This patient
harboured a missense variant (c.7534C > T; variant of
uncertain significance) localized within one of the
BRCA2 probes of SALSA® MLPA® P045, which may have
interfered in the result and reduced the signal of exon
15. A confirmatory MLPA reaction, using SALSA®
MLPA®P077, employing different probes, did not reveal
a reduced peak for exon 15, indicating the absence of a
true deletion.
Table 2 BRCA1/2 mutations in ovarian cancer patients: clinical aspects and molecular description
ID HGVS cDNA HGVS protein BIC name Type Age Ancestry HT CS FH Reference
BRCA1
21 c.791_794delGTTC p.Ser264Metfs 910del4 F 50–59 BRZ S III NC [30]
18 c.961_962delTG p.(Trp321fs) ND F 50–59 BRZ S III - Current Study
49 c.1687C > T p.Gln563Ter 1806C > T N 40–49 BRZ S III + [30]
39 c.2215A > T p.Lys739Ter K739X N 50–59 (BC ≤50) BRZ S III NC [BIC]
17 c.3331_3334delCAAG p.Gln1111Asnfs 3450del4 F 30–39 IND/BRZ/EUR S III + [5, 11, 13, 30]
42 c.3331_3334delCAAG p.Gln1111Asnfs 3450del4 F 50–59 IND/BRZ/EUR S III + [5, 11, 13, 30]
107 c.3331_3334delCAAG p.Gln1111Asnfs 3450del4 F 50–59 (BC ≤50) BRZ/EUR E III + [5, 11, 13, 30]
50 c.4484G > T p.Arg1495Met R1495M M 30–39 BRZ S III - [4]
37 c.4484G > T p.Arg1495Met R1495M M 50–59 IND/BRZ S IV + [4]
106 c.4675+1G > A - IVS15+1G >A Ss 40–49 BRZ/EUR S III - [4]
67 c.5074+2 T > C - IVS17+2 T >C Ss 60–69 BRZ/EUR S III + [BIC]
85 c.5098_5098delA p.Thr1700Hisfs 5217delA F 40–49 BRZ/EUR S IV - [BIC]
26 c.5266dupC p.Gln1756Profs 5382insC F 50–59 EUR S IV + [11, 13, 32]
56 c.5266dupC p.Gln1756Profs 5382insC F 50–59 (BC ≤50) BRZ S III + [11, 13, 32]
108 c.5266dupC p.Gln1756Profs 5382insC F 40–49 IND/BRZ S III UK [11, 13, 32]
101 Exon 1–2 deleteda - - LGR 50–59 BRZ S III + [37, 38]
9 Exon 5–7 deleteda - - LGR 50–59 BRZ /EUR S III - [37, 38]
BRCA2
74 c.1963_1963delC p.(Pro655fs) ND F 60–69 EUR S III + Current Study
102 c.5576_5579delTTAA p.Ile1859_Lys1860?fs 5804del4 F 60–69 JAP S III + [30]
ID patient identification; Type: F frameshift, N nonsense, M missense, Ss splice site, LGR large genomic rearrangement; Age in years (range); BC previous breast cancer
history; Ancestry: BRZ Brazilian, IND Indigenous, EUR European, JAP Japanese, CS clinical stage, HT histological type, S serous, E endometrioid, FH family history for breast
and/or ovarian cancer: (+): present, (−): absent, NC not completely known, UK unknown, BIC breast cancer information core, ND not described mutation
aIndicates mutations detected by MLPA
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All patients were checked for c.1100delC point muta-
tion of CHEK2, however, none was detected.
There was no difference between the median age at
diagnosis from patients who were BRCA1/2 mutation
carriers or non-carriers. All mutation carriers were diag-
nosed with advanced disease (clinical stages III/IV).
Considering the birth place, nine out of 57 women
(15.8%) born in the Southeast region and seven out of
28 (25%) born in the Northeast region harboured a
BRCA1/2 mutation. Among 38 patients who reported
Brazilian only ancestry, seven were BRCA1/2 mutation
carriers (18.4%) and among seven patients who reported
at least one indigenous ancestry four (57.1%) were muta-
tion carriers (Table 1). Among the 68 patients with in-
formative family history for breast and/or ovarian
cancer, 35.5% with and 13.5% without any affected first
and/or second-degree relatives were BRCA1/2 mutations
carriers. Although all two patients who were BRCA2
mutation carriers were aged at least 60 years, almost all
(16/17) women who were BRCA1 mutation carriers were
aged less than 60.
Nineteen variants of uncertain significance (VUS) were
detected, two in BRCA1 and seventeen in BRCA2 gene.
Among the VUS, five distinct missense variants were
identified, one in BRCA1 and four in BRCA2, among
which, three, BRCA1 c.5348 T > C, BRCA2 c.3515C > T
and BRCA2 c.8351G > A were predicted deleterious in at
least three of four mutation function prediction models
(Polyhen-2, SIFT, Provean or Align GVGD) (Table 3).
The remaining VUS were synonymous (n = 4) or were
located in intronic regions, at least eight nucleotides
away from the intron-exon boundary (n = 10).
Discussion
In this cohort, 19 out of 100 unselected Brazilian ovarian
cancer patients, were BRCA1/2 mutation carriers,
mainly in the BRCA1 gene (n = 17). In BRCA1 gene, 12
different mutations were detected, including one new
frameshift and two large deletions. In BRCA2 gene, only
two pathogenic mutations, including a new frameshift
mutation were found. In addition, another five missense
VUS were identified in five different patients. Concern-
ing their ancestry, 18.4% of the patients who reported
Brazilian only ancestors and 26.3% of those who re-
ported European ancestry, in at least one side of the
family, were mutation carriers. In addition, 35.5% of the
patients with and 13.5% of the patients without first
and/or second-degree relatives with breast and/or ovar-
ian cancer were BRCA1/2 mutations carriers.
A prevalence of 19% BRCA1/2 mutation rate seems
somewhat higher than previously described for women
with ovarian cancer from other countries, such as
Canada (13.4%) [4] and Colombia (15%) [5]. However,
one might claim that we had a cohort enriched in BRCA
mutation carriers, due to time selection, taking into con-
sideration that germline mutation in BRCA1 or BRCA2
is associated with an improved 5-year overall survival
and that a few patients were diagnosed long before their
enrolment in the project [27, 28]. Contrary to this is the
fact that the mean time between dates of diagnosis and
enrolment was similar in both BRCA1/2 mutation and
BRCA1/2 wild type carriers.
In accordance with previous studies, our patients with
ovarian cancer were mainly BRCA1 mutation carriers
[4], however only one out of 12 different mutations,
c.2215A > T, was located in a putative ovarian cancer
cluster region (OCCR) of exon 11, an hypothesized
region associated with increased risk estimates for ovarian
cancer [29]. Remarkably was that this patient had breast
cancer before the ovarian cancer.
Three mutations in BRCA1 gene were detected more
than once: c.3331_3334delCAAG, c.5266dupC and
c.4484G > T. BRCA1 c.3331_3334delCAAG mutation in
exon 11, is also a frequent mutation in ovarian cancer
Table 3 Analysis of missense variants from BRCA1/2 gene of uncertain significance using mutation function prediction models
Gene Exon HDVS cDNA HGVS protein PolyPhen SIFT Provean Align GVGD Human splice finder ID
BRCA1 22 c.5348 T > C p.Met1783Thr Probably Damaging Damaging Neutral Class C45 - 94
BRCA2 11 c.2350A > G p.Met784Val Benign Tolerated Neutral Class C0 Activation of an exonic cryptic
donor site / Creation of an exonic
ESS site / Alteration of an exonic
ESE site.
35
11 c.3515C > T p.Ser1172Leu Probably Damaging Damaging Deleterious Class C0 Creation of an exonic ESS site/
Alteration of an exonic ESE site.
25
15 c.7534C > T p.Leu2512Phe Probably Damaging Damaging Neutral Class C0 Alteration of an intronic ESS site. 47
19 c.8351G > A p.Arg2784Gln Probably Damaging Damaging Neutral Class C35 Activation of an exonic cryptic
acceptor site
111
Presence of one or more cryptic
branch point.
HGVS Human Genome Variation Society, PolyPhen: Variant Benign, Possibly damaging and Probably damaging; SIFT: Variant Tolerated (benign) or Damaging;
Provean: Neutral or Deleterius; Align GVGD: Class C0 (Less likely to interfere in protein function), C15, C25, C35, C45, C55, C65 (More likely to interfere in protein
function); ID: patient identification
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patients from Colombia [5] and Spain [30], but mostly
rare in Canadian patients [4]. This mutation was already
reported in Brazilian patients [11, 13]. A previous haplo-
type study suggested that it could represent a founder
effect of Spanish origin [31], and curiously all our three
patients reported European ancestries, two of them from
the Iberian Peninsula, more specifically, from Portugal.
Another frequent mutation detected in our ovarian
cancer patients was the one commonly found in the
Ashkenazi Jewish, BRCA1 c.5266dupC (5382insC), how-
ever none of them reported Jewish ancestry. This muta-
tion is one of the most commonly found in Brazilian
breast and/or ovarian cancer patients [11, 13, 32]. In
addition, one meta-analysis reported that BRCA1
c.5266dupC is the fourth most prevalent in Latin America
[33]. Interestingly, a haplotype study revealed that BRCA1
c.5266dupC originated from a single common ancestor
around 1800 years ago in northern Russia and spread to
various populations, including Ashkenazi Jewish people
[34]. In accordance, a common origin for this mutation in
our country was previously reported for breast cancer
patients [35, 36].
Two patients presented the BRCA1 c.4484G > T mis-
sense mutation, which involves the last nucleotide of
exon 14, resulting in skipping of exon 14. This mutation
was previously found in ovarian cancer patients and
associated with causality [4]. Other mutations in BRCA1
detected in the present work were already described, as
shown in Table 2, except for c.961_962delTG frame-
shift variant, characterized for the first time in this
study.
Comparing BRCA1 mutations detected in our study of
Brazilian ovarian cancer patients with those reported in
breast cancer patients [11–13], it is interesting to ob-
serve that they are concordant with respect to the most
recurrent variant, BRCA1 c.5266dupC, that also is one
of the most commonly found in Latin American breast
cancer patients [33]. However, there is a difference in
relation to variant c.3331_3334delCAAG, that was rarely
found in patients with breast cancer.
Only two pathogenic mutations were detected in
BRCA2 gene, including one novel frameshift mutation,
c.1963_1963delC, and another one, c.5576_5579delT
TAA, in a patient with Japanese ancestry. The latter mu-
tation is located in an ovarian cancer cluster region
(OCCR) of exon 11, which is bound by c.3249 and
c.5681 [29].
Another mechanism of gene inactivation, namely the
rearrangement of large tracts of genomic DNA, was de-
tected in two patients (BRCA1: exon 1–2 deleted and
exon 5–7 deleted). Deletion of exons 1a-2, which may
affect production and/or stability of the transcript [37, 38],
is the third most frequent in Latin American breast cancer
patients [33]. In your study, this deletion was identified in
a woman who was diagnosed with ovarian cancer at the
age of 52 and reported a family history of ovarian cancer
and colorectal cancer. The removal of exons 5–7 from
gene BRCA1 causes a frameshift in protein translation
[37]. This deletion was identified in a woman with ovarian
cancer aged 57 years, who reported an European ancestry
but did not recall any family history of breast and/or ovar-
ian cancer. This mutation was previously described in one
German patient with positive family history for breast can-
cer and ovarian cancer [37] and one Italian patient with
breast cancer [38].
In our study, CHEK2 mutations were not detected, in ac-
cordance with other previous studies, that in total analysed
an additional 21 Brazilian ovarian cancer patients. [12, 39].
A strength of our study is that the entire BRCA1/2
gene was screened for the first time in a population of
women with epithelial ovarian cancer from Brazil, unse-
lected for age and family history. A weakness however, is
the small sample size was analysed. In a recently pub-
lished study, the prevalence of a panel of eight mutations
in BRCA1 or BRCA2 genes, mainly detected in Ashkenazi
Jewish or people from Russia or Poland, was investigated
in 106 ovarian cancer patients treated at the Federal
Hospital in Minas Gerais state, which is neighbour to
São Paulo state. None of the participants were found
to carry any of the genotyped mutations [40]. In our
study, among nine patients born in Minas Gerais
state, one harboured a BRCA1 mutation (c.4675 + 1G >A)
not investigated in the previous study (Table 2). In
addition, in another study performed in our city, a few pa-
tients with ovarian cancer were enrolled for entire
BRCA1/2 gene sequencing. BRCA1 mutation was
detected in one out of three patients diagnosed with ovar-
ian cancer and in four out of nine with both breast and
ovarian cancer [12].
Considering that Brazil is a huge country inhabited by
people from different origins and that our patients come
from different regions of the country, we evaluated
BRCA1/2 mutation status considering their birth place
and ancestry. Our study mainly reflects Brazilian pa-
tients born in São Paulo state or in the Northeast region
of Brazil with Brazilian and/or European ancestries. In
the current study 14 different variants were detected in
100 patients. These different variants may reflect the
ethnic diversity and miscegenation of people that live in
Brazil. Corroborating this hypothesis, genetic polymor-
phisms analysis have already revealed that the average
Brazilian population has unique characteristics, compre-
hending a mixture of European, African and Amerindian
ancestry genes [41]. It is interesting to observe that, 15
out of 16 BRCA1 mutation carriers, reported Brazilian
ancestry in one or both sides of the family, which means
that, as long as they were aware, their ancestors were
born in Brazil.
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Conclusion
In this cohort of epithelial ovarian cancer patients, the
prevalence of BRCA1/2 mutation was 19%, mostly de-
tected in different gene locations. Two novel frameshift
mutations were identified, one in BRCA1 and one in
BRCA2, as well as two large deletions. These data
emphasize that entire gene sequencing of both BRCA1
and BRCA2 as well as MLPA screening should be
offered to all Brazilian ovarian cancer patients.
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